Medical Treatment of Nasal Polyposis

  • İhsan Kuzucu
  • İsmail Güler
  • Nuray Bayar Muluk


Nasal polyps cause nasal blockage, runny nose, and decrease in or loss of olfaction, but their etiology is actually not known. The treatment of chronic rhinosinusitis (CRS) with nasal polyposis is directed at dealing with these symptoms, and consists of both surgical and medical remedies; nevertheless there is no treatment protocol that is universally recognized. The treatment of nasal polyps depends on the etiologic elements. However, in the majority of cases, this is not clear. Even when the patient has allergic background, no clinical proof demonstrates that the treatment of these allergies could minimize or eradicate polyps. Since the main etiology in the majority of cases is inflammation, medical treatment consists of nonspecific therapies for this inflammation related problem. Nasal corticosteroid sprays may diminish or slow down the development of small nasal polyps; nevertheless they are rather not effective in massive nasal polyposis. Intranasal steroids are most beneficial in the postoperative interval to protect against or slow down regrowth of the polyps. Oral steroids are one of the mainstays for the medical treatment of nasal polyposis. Antibiotics, anti-IgE, anti-IL-5, antihistamines, antimycotics (topical amphotericin B), furosemide, immunosuppressants, leukotriene antagonists, Aspirin desensitization, capsaicin, nasal decongestants, mucolytics, postoperative saline douches or spray, manuka honey, and proton pump inhibitors are also used. In this chapter, alternatives of medical treatment for nasal polyposis are described.


Nasal polyposis Medical treatment Nasal corticosteroid sprays Anti-IgE Anti-IL-5 Antihistamines 


  1. 1.
    Bhattacharyya N, Harvey RJ, Rosenfeld RM. Cochrane corner: extracts from the Cochrane library: interventions for chronic rhinosinusitis with polyps. Otolaryngol Head Neck Surg. 2015;153(3):315–9.PubMedGoogle Scholar
  2. 2.
    Archer SM. Nonsurgical treatment of nasal polyps. In: Meyers AD (editor). Medscape. Accessed 03 Aug 2015.
  3. 3.
    Chalton R, Mackay IS. Double blind, placebo controlled trial of betamethasone nasal drops for nasal polyposis. BMJ. 1985;291:788.PubMedGoogle Scholar
  4. 4.
    Ruhno J, Andersson BN, Denburg J, Andersson M, Hitch D, Lapp P, et al. A double-blind comparison of intranasal budesonide with placebo for nasal polyposis.J Allergy Clin Immunol 1990;86:946–953.PubMedGoogle Scholar
  5. 5.
    Mygind N, Brahe Pedersen C, Prytz S, Sorensen H. Treatment of nasal polyps with intranasal beclomethasone dipropionate aerosol. Clin Allerg. 1975;5:159–64.Google Scholar
  6. 6.
    Lund VJ. Diagnosis and treatment of nasal polyps. BMJ. 1995;311:141–14.Google Scholar
  7. 7.
    Rudmik L, Schlosser RJ, Smith TL, Soler ZM. Impact of topical nasal steroid therapy on symptoms of nasal polyposis: a meta-analysis. Laryngoscope. 2012;122(7):1431–7.PubMedGoogle Scholar
  8. 8.
    Tos M, Svendstrup F, Arndal H, Orntoft S, Jakobsen J, Borum P, et al. Efficacy of an aqueous and a powder formulation of nasal budesonide compared in patients with nasal polyps. Am J Rhinol. 1998;12(3):183–9.PubMedGoogle Scholar
  9. 9.
    Keith P, Nieminen J, Hollingworth K, Dolovich J. Efficacy and tolerability of fluticasone propionate nasal drops 400 microgram once daily compared with placebo for the treatment of bilateral polyposis in adults. Clin Exp Allergy. 2000;30(10):1460–8.PubMedGoogle Scholar
  10. 10.
    European Academy of Allergology and Clinical Immunology. European position paper on rhinosinusitis and nasal polyps. Rhinol Suppl. 2005;18:1–87.Google Scholar
  11. 11.
    McClay JE. Nasal polyps treatment & management. In: Isaacson GC (editor). Medscape. Accessed 03 Aug 2015.
  12. 12.
    Van Zele T, Gevaert P, Holtappels G, Beule A, Wormald PJ, Mayr S, et al. Oral steroids and doxycycline: two different approaches to treat nasal polyps. J Allergy Clin Immunol. 2010;125(5):1069–1076.e4.PubMedGoogle Scholar
  13. 13.
    Martinez-Devesa P, Patiar S. Oral steroids for nasal polyps. Cochrane Database Syst Rev. 2011:CD005232.Google Scholar
  14. 14.
    Kirtsreesakul V, Wongsritrang K, Ruttanaphol S. Clinical efficacy of a short course of systemic steroids in nasal polyposis. Rhinology. 2011;49(5):525–32.PubMedGoogle Scholar
  15. 15.
    Moss WJ, Kjos KB, Karnezis TT, Lebovits MJ. Intranasal steroid injections and blindness: our personal experience and a review of the past 60 years. Laryngoscope. 2015;125(4):796–800. Epub 2014 Nov 6CrossRefPubMedGoogle Scholar
  16. 16.
    Schalek P, Petras P, Klement V, Hahn A. Short-term antibiotics treatment in patients with nasal polyps and enterotoxins producing Staphylococcus aureus strains. Eur Arch Otorhinolaryngol. 2009;266(12):1909–13.PubMedGoogle Scholar
  17. 17.
    Fokkens WJ, Lund VJ, Mullol J, et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2012. Rhinology. 2012;supplement 23:1–298.Google Scholar
  18. 18.
    Yamada T, Fujieda S, Mori S, Yamamoto H, Saito H. Macrolide treatment decreased the size of nasal polyps and IL-8 levels in nasal lavage. Am J Rhinol. 2000;14(3):143–8.PubMedGoogle Scholar
  19. 19.
    Ichimura K, Shimazaki Y, Ishibashi T, Higo R. Effect of new macrolide roxithromycin upon nasal polyps associated with chronic sinusitis. Auris Nasus Larynx. 1996;23:48–56.PubMedGoogle Scholar
  20. 20.
    Suzuki H, Shimomura A, Ikeda K, Oshima T, Takasaka T. Effects of long-term low-dose macrolide administration on neutrophil recruitment and IL-8 in the nasal discharge of chronic sinusitis patients. Tohoku J Exp Med. 1997;182(2):115–24.PubMedGoogle Scholar
  21. 21.
    Guglielmo M, Gulotta C, Mancini F, Sacchi M, Tarantini F. Recalcitrant nasal polyposis: achievement of total remission following treatment with omalizumab. J Investig Allergol Clin Immunol. 2009;19(2):158–9.PubMedGoogle Scholar
  22. 22.
    Grundmann SA, Hemfort PB, Luger TA, Brehler R. Anti-IgE (omalizumab): a new therapeutic approach for chronic rhinosinusitis. J Allergy Clin Immunol. 2008;121(1):2578.Google Scholar
  23. 23.
    Penn R, Mikula S. The role of anti-IgE immunoglobulin therapy in nasal polyposis: a pilot study. Am J Rhinol. 2007;21(4):428–32.PubMedGoogle Scholar
  24. 24.
    Vennera Mdel C, Picado C, Mullol J, Alobid I, Bernal-Sprekelsen M. Efficacy of omalizumab in the treatment of nasal polyps. Thorax. 2011;66(9):824–5.PubMedGoogle Scholar
  25. 25.
    Cox L, Lieberman P, Wallace D, Simons FE, Finegold I, Platts-Mills T, et al. American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma & Immunology Omalizumab-Associated Anaphylaxis Joint Task Force follow-up report. J Allergy Clin Immunol. 2011;128(1):210–2.PubMedGoogle Scholar
  26. 26.
    Omalizumab: a second look in severe persistent asthma: new adverse effects. Prescrire Int. 2011;20(115):90–2.Google Scholar
  27. 27.
    Mepolizumab: 240563, anti-IL-5 monoclonal antibody - GlaxoSmithKline, anti-interleukin-5 monoclonal antibody - GlaxoSmithKline, SB 240563. Drugs R D. 2008;9(2):125–30.Google Scholar
  28. 28.
    Walsh GM. Reslizumab, a humanized antiIL-5 mAb for the treatment of eosinophil-mediated inflammatory conditions. Curr Opin Mol Ther. 2009;11(3):329–36.PubMedGoogle Scholar
  29. 29.
    Gevaert P, Van Bruaene N, Cattaert T, Van Steen K, Van Zele T, Acke F, et al. Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis. J Allergy Clin Immunol. 2011:27.Google Scholar
  30. 30.
    Haye R, Aanesen JP, Burtin B, Donnelly F, Duby C. The effect of cetirizine on symptoms and signs of nasal polyposis. J Laryngol Otol. 1998;112(11):1042–6.PubMedGoogle Scholar
  31. 31.
    Sacks PL, Harvey RJ, Rimmer J, Gallagher RM, Sacks R. Topical and systemic antifungal therapy for the symptomatic treatment of chronic rhinosinusitis. Cochrane Database Syst Rev. 2011;8:CD008263.Google Scholar
  32. 32.
    Stankiewicz JA, Musgrave BK, Scianna JM. Nasal amphotericin irrigation in chronic rhinosinusitis. Curr Opin Otolaryngol Head Neck Surg. 2008;16(1):44–6.PubMedGoogle Scholar
  33. 33.
    Ebbens FA, Georgalas C, Fokkens WJ. Fungus as the cause of chronic rhinosinusitis: the case remains unproven. Curr Opin Otolaryngol Head Neck Surg. 2009;17(1):43–9.PubMedGoogle Scholar
  34. 34.
    Passali D, Bernstein JM, Passali FM, Damiani V, Passali GC, Bellussi L. Treatment of recurrent chronic hyperplastic sinusitis with nasal polyposis. Arch Otolaryngol Head Neck Surg. 2003;129(6):656–9.PubMedGoogle Scholar
  35. 35.
    Passali D, Mezzedimi C, Passali GC, Bellussi L. Efficacy of inhalation form of furosemide to prevent postsurgical relapses of rhinosinusal polyposis. ORL J Otorhinolaryngol Relat Spec. 2000;62(6):307–10.PubMedGoogle Scholar
  36. 36.
    Corrigan CJ. Asthma refractory to glucocorticoids: the role of newer immunosuppressants. Am J Respir Med. 2002;1(1):47–54.PubMedGoogle Scholar
  37. 37.
    Asplund MS, Hagberg H, Holmstrom M. Chemotherapy in severe nasal polyposis--a possible beneficial effect? A report of three cases. Rhinology. 2010;48(3):374–6.PubMedGoogle Scholar
  38. 38.
    Buyukozturk S, Gelincik A, Aslan I, Aydin S, Colakoglu B, Dal M. Methotrexate: can it be a choice for nasal polyposis in aspirin exacerbated respiratory disease? J Asthma. 2009;46(10):1037–41.PubMedGoogle Scholar
  39. 39.
    Parnes SM, Chuma AV. Acute effects of antileukotrienes on sinonasal polyposis and sinusitis. Ear Nose Throat J. 2000;79(1):1820–24-5.Google Scholar
  40. 40.
    Ulualp SO, Sterman BM, Toohill RJ. Antileukotriene therapy for the relief of sinus symptoms in aspirin triad disease. Ear Nose Throat J. 1999;78(8):604–6, 608, 613, passimPubMedGoogle Scholar
  41. 41.
    Ragab S, Parikh A, Darby YC, Scadding GK. An open audit of montelukast, a leukotriene receptor antagonist, in nasal polyposis associated with asthma. Clin Exp Allergy. 2001;31(9):1385–91.PubMedGoogle Scholar
  42. 42.
    Parnes SM, Chuma AV. Acute effects of antileukotrienes on sinonasal polyposis and sinusitis. Ear Nose Throat J. 2000;79(1):18–20. 4-5PubMedGoogle Scholar
  43. 43.
    Stevenson DD, Hankammer MA, Mathison DA, Christiansen SC, Simon RA. Aspirin desensitization treatment of aspirin-sensitive patients with rhinosinusitis-asthma: long-term outcomes. J Allergy Clin Immunol. 1996;98(4):751–8.PubMedGoogle Scholar
  44. 44.
    Stevenson DD. Aspirin desensitization in patients with AERD. Clin Rev Allergy Immunol. 2003;24(2):159–68.PubMedGoogle Scholar
  45. 45.
    Mardiney M, Borish L. Aspirin desensitization for chronic hyperplastic sinusitis, nasal polyposis, and asthma triad. Arch Otolaryngol Head Neck Surg. 2001;127(10):1287.PubMedGoogle Scholar
  46. 46.
    Nucera E, Schiavino D, Milani A, Del Ninno M, Misuraca C, Buonomo A, et al. Effects of lysine-acetylsalicylate (LAS) treatment in nasal polyposis: two controlled long term prospective follow up studies. Thorax. 2000;55(Suppl 2):S75–8.PubMedPubMedCentralGoogle Scholar
  47. 47.
    Filiaci F, Zambetti G, Luce M, Ciofalo A. Local treatment of nasal polyposis with capsaicin: preliminary findings. Allergol Immunopathol (Madr). 1996;24(1):13–8.Google Scholar
  48. 48.
    Baudoin T, Kalogjera L, Hat J. Capsaicin significantly reduces sinonasal polyps. Acta Otolaryngol. 2000;120(2):307–11.PubMedGoogle Scholar
  49. 49.
    Zheng C, Wang Z, Lacroix JS. Effect of intranasal treatment with capsaicin on the recurrence of polyps after polypectomy and ethmoidectomy. Acta Otolaryngol. 2000;120(1):62–6.PubMedGoogle Scholar
  50. 50.
    Sancho R, Lucena C, Macho A, Calzado MA, Blanco-Molina M, Minassi A, et al. Immunosuppressive activity of capsaicinoids: capsiate derived from sweet peppers inhibits NF-kappaB activation and is a potent anti-inflammatory compound in vivo. Eur J Immunol. 2002;32(6):1753–63.PubMedGoogle Scholar
  51. 51.
    Johansson L, Oberg D, Melen I, Bende M. Do topical nasal decongestants affect polyps? Acta Otolaryngol. 2006;126(3):288–90.PubMedGoogle Scholar
  52. 52.
    Pigret D, Jankowski R. Management of post-ethmoidectomy crust formation: randomized single-blind clinical trial comparing pressurized seawater versus antiseptic/mucolytic saline. Rhinology. 1996;34(1):38–40.PubMedGoogle Scholar
  53. 53.
    Freeman SR, Sivayoham ES, Jepson K, de Carpentier J. A preliminary randomised controlled trial evaluating the efficacy of saline douching following endoscopic sinus surgery. Clin Otolaryngol. 2008;33(5):462–5.PubMedGoogle Scholar
  54. 54.
    Pinto JM, Elwany S, Baroody FM, Naclerio RM. Effects of saline sprays on symptoms after endoscopic sinus surgery. Am J Rhinol. 2006;20(2):191–6.PubMedGoogle Scholar
  55. 55.
    Thamboo A, Philpott C, Javer A, Clark A. Single-blind study of manuka honey in allergic fungal rhinosinusitis. J Otolaryngol Head Neck Surg. 2011;40(3):238–43.PubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • İhsan Kuzucu
    • 1
  • İsmail Güler
    • 1
  • Nuray Bayar Muluk
    • 2
  1. 1.Department of OtorhinolaryngologyUniversity of Health Sciences, Ankara Numune Training and Research HospitalAnkaraTurkey
  2. 2.Department of Otorhinolaryngology, Medical FacultyKırıkkale UniversityKırıkkaleTurkey

Personalised recommendations